Evogene Ltd.Evogene Ltd.Evogene Ltd.

Evogene Ltd.

No trades
See on Supercharts
Market capitalization
‪32.89 M‬USD
‪−23.88 M‬USD
‪5.64 M‬USD
‪49.75 M‬
Beta (1Y)

About Evogene Ltd.

Ofer Haviv
Employees (FY)
Evogene Ltd. engages in the development and commercialization of a computer-biological platform for improving the development processes of products in the field of life sciences. It operates through the following segments: Agriculture, Industrial Applications, and Human Health. The Agriculture segment develops seed traits, agrochemical products, and agro biological products to improve plant performance. The Industrial Applications focuses on the development and commercialization of improved castor bean seeds for industrial uses. The Human Health segment involves discovery and development of human microbiome-based therapeutics. The company was founded by Amir Barzilay and Hagai Karchi on October 10, 1999 and is headquartered in Rehovot, Israel.
Revenue to profit conversion
Debt level and coverage

See all ideas 

Summarizing what the indicators are suggesting.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of EVGN is 0.6597 USD — it has increased by 1.48% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Evogene Ltd. stocks are traded under the ticker EVGN.
Evogene Ltd. is going to release the next earnings report on May 28, 2024. Keep track of upcoming events with our Earnings Calendar.
EVGN stock is 7.17% volatile and has beta coefficient of 2.27. Check out the list of the most volatile stocks — is Evogene Ltd. there?
EVGN earnings for the last quarter are −0.08 USD per share, whereas the estimation was −0.16 USD resulting in a 48.94% surprise. The estimated earnings for the next quarter are −0.14 USD per share. See more details about Evogene Ltd. earnings.
Evogene Ltd. revenue for the last quarter amounts to ‪3.77 M‬ USD despite the estimated figure of ‪1.20 M‬ USD. In the next quarter revenue is expected to reach ‪475.00 K‬ USD.
Yes, you can track Evogene Ltd. financials in yearly and quarterly reports right on TradingView.
EVGN stock has fallen by 5.37% compared to the previous week, the month change is a 14.35% fall, over the last year Evogene Ltd. has showed a 9.95% increase.
EVGN net income for the last quarter is ‪−6.60 M‬ USD, while the quarter before that showed ‪−3.98 M‬ USD of net income which accounts for −65.69% change. Track more Evogene Ltd. financial stats to get the full picture.
Today Evogene Ltd. has the market capitalization of ‪32.89 M‬, it has increased by 4.78% over the last week.
No, EVGN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, EVGN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Evogene Ltd. stock right from TradingView charts — choose your broker and connect to your account.
EVGN reached its all-time high on Dec 12, 2013 with the price of 20.3899 USD, and its all-time low was 0.4502 USD and was reached on Oct 24, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 23, 2024, the company has 142.00 employees. See our rating of the largest employees — is Evogene Ltd. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Evogene Ltd. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Evogene Ltd. stock shows the strong sell signal. See more of Evogene Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Evogene Ltd. future price: according to them, EVGN price has a max estimate of 3.00 USD and a min estimate of 1.85 USD. Read a more detailed Evogene Ltd. forecast: see what analysts think of Evogene Ltd. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Evogene Ltd. EBITDA is ‪−23.90 M‬ USD, and current EBITDA margin is −421.61%. See more stats in Evogene Ltd. financial statements.